Carbohydrate polymers in cancer theranostics: Smart solutions for advanced diagnosis and therapy

IF 6 2区医学 Q2 MATERIALS SCIENCE, BIOMATERIALS

Materials Science & Engineering C-Materials for Biological Applications Pub Date : 2025-09-24 DOI:10.1016/j.bioadv.2025.214522

Preeti Rajesh , Harsimran Kaur , Vishal Ahuja , Deepak Sharma , Gholamreza Abdi

{"title":"Carbohydrate polymers in cancer theranostics: Smart solutions for advanced diagnosis and therapy","authors":"Preeti Rajesh , Harsimran Kaur , Vishal Ahuja , Deepak Sharma , Gholamreza Abdi","doi":"10.1016/j.bioadv.2025.214522","DOIUrl":null,"url":null,"abstract":"<div><div>The versatility and chemical flexibility of polymeric carbohydrates have significantly advanced the field of cancer therapy and theranostics. The controlled release, biodegradability, and biocompatibility of these polymers are currently being researched intensively for their utility in targeted drug delivery systems for the treatment of breast and colon cancer, among others. Due to their abundance, low <em>in vivo</em> toxicity, and amenability to functionalization, these polymers are becoming more and more popular as therapeutic nanoparticles and as nanoplatforms for simultaneous drug delivery and imaging. Functionalized carbohydrate polymers can improve the accuracy of cancer detection using molecular imaging methods. The fusion of imaging modalities with drug delivery systems enables a controlled and targeted release of drugs, hence improving therapeutic efficacy with fewer side effects. The inherent immunomodulatory property of such systems also enables modulation of immune cell function and restoration of the tumor microenvironment, hence facilitating anti-cancer immunity. Through stimulus-responsive mechanisms, advanced polymeric systems can respond to the specific conditions within individual tumors, enhancing cancer treatment efficacy. Advances in glycobiology and nanotechnology have improved the potential of carbohydrate polymers, and identified as potential candidates for next-generation cancer theranostics. Future research and translation of findings to clinical applications will likely result in more personalized and effective ways of treating cancer.</div></div>","PeriodicalId":51111,"journal":{"name":"Materials Science & Engineering C-Materials for Biological Applications","volume":"179 ","pages":"Article 214522"},"PeriodicalIF":6.0000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Science & Engineering C-Materials for Biological Applications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772950825003498","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

The versatility and chemical flexibility of polymeric carbohydrates have significantly advanced the field of cancer therapy and theranostics. The controlled release, biodegradability, and biocompatibility of these polymers are currently being researched intensively for their utility in targeted drug delivery systems for the treatment of breast and colon cancer, among others. Due to their abundance, low in vivo toxicity, and amenability to functionalization, these polymers are becoming more and more popular as therapeutic nanoparticles and as nanoplatforms for simultaneous drug delivery and imaging. Functionalized carbohydrate polymers can improve the accuracy of cancer detection using molecular imaging methods. The fusion of imaging modalities with drug delivery systems enables a controlled and targeted release of drugs, hence improving therapeutic efficacy with fewer side effects. The inherent immunomodulatory property of such systems also enables modulation of immune cell function and restoration of the tumor microenvironment, hence facilitating anti-cancer immunity. Through stimulus-responsive mechanisms, advanced polymeric systems can respond to the specific conditions within individual tumors, enhancing cancer treatment efficacy. Advances in glycobiology and nanotechnology have improved the potential of carbohydrate polymers, and identified as potential candidates for next-generation cancer theranostics. Future research and translation of findings to clinical applications will likely result in more personalized and effective ways of treating cancer.

查看原文本刊更多论文

碳水化合物聚合物在癌症治疗：先进诊断和治疗的智能解决方案。

高分子碳水化合物的多功能性和化学柔韧性极大地推动了癌症治疗和治疗学领域的发展。这些聚合物的控释、生物可降解性和生物相容性目前正在深入研究，以用于治疗乳腺癌和结肠癌等靶向药物输送系统。由于它们的丰度、低体内毒性和易于功能化，这些聚合物作为治疗纳米粒子和同时给药和成像的纳米平台越来越受欢迎。功能化碳水化合物聚合物可以提高分子成像方法检测癌症的准确性。成像模式与药物传递系统的融合使药物的控制和靶向释放成为可能，从而提高治疗效果，减少副作用。这些系统固有的免疫调节特性还可以调节免疫细胞功能和恢复肿瘤微环境，从而促进抗癌免疫。通过刺激反应机制，先进的聚合物系统可以对个体肿瘤内的特定情况做出反应，提高癌症治疗效果。糖生物学和纳米技术的进步提高了碳水化合物聚合物的潜力，并被确定为下一代癌症治疗的潜在候选者。未来的研究和将发现转化为临床应用可能会产生更个性化和更有效的治疗癌症的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Materials Science & Engineering C-Materials for Biological Applications 工程技术-材料科学：生物材料

CiteScore

17.80

自引率

0.00%

发文量

501

审稿时长

27 days

期刊介绍： Biomaterials Advances, previously known as Materials Science and Engineering: C-Materials for Biological Applications (P-ISSN: 0928-4931, E-ISSN: 1873-0191). Includes topics at the interface of the biomedical sciences and materials engineering. These topics include: • Bioinspired and biomimetic materials for medical applications • Materials of biological origin for medical applications • Materials for "active" medical applications • Self-assembling and self-healing materials for medical applications • "Smart" (i.e., stimulus-response) materials for medical applications • Ceramic, metallic, polymeric, and composite materials for medical applications • Materials for in vivo sensing • Materials for in vivo imaging • Materials for delivery of pharmacologic agents and vaccines • Novel approaches for characterizing and modeling materials for medical applications Manuscripts on biological topics without a materials science component, or manuscripts on materials science without biological applications, will not be considered for publication in Materials Science and Engineering C. New submissions are first assessed for language, scope and originality (plagiarism check) and can be desk rejected before review if they need English language improvements, are out of scope or present excessive duplication with published sources. Biomaterials Advances sits within Elsevier''s biomaterials science portfolio alongside Biomaterials, Materials Today Bio and Biomaterials and Biosystems. As part of the broader Materials Today family, Biomaterials Advances offers authors rigorous peer review, rapid decisions, and high visibility. We look forward to receiving your submissions!